Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an update.
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a non‑transferable contingent value right, expanding its portfolio in autoimmune disease treatments. The CVR will give Kezar shareholders potential upside from the development or sale of zetomipzomib, proceeds from certain partnerships, and Kezar’s closing net cash above $50 million.
Kezar’s board unanimously backed the deal following a strategic review, citing Aurinia’s track record in autoimmune drug development as a key factor. The transaction, supported by Tang Capital Partners and structured via a tender offer to be launched by April 13, 2026, is expected to close in the second quarter of 2026, positioning Aurinia to advance zetomipzomib in autoimmune hepatitis and related indications.
The most recent analyst rating on (AUPH) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
The score is driven primarily by the improved fundamentals (revenue scale-up, strong cash generation, and low leverage) and a generally positive earnings call with double-digit 2026 growth guidance. These strengths are tempered by weak technical signals and uncertainties around the sustainability of reported profitability given the material one-time tax benefits, alongside competitive and regulatory risks.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its lead commercial product is LUPKYNIS, the first FDA‑approved oral treatment for adult patients with active lupus nephritis, and it is also developing aritinercept, a dual BAFF/APRIL inhibitor for autoimmune indications.
Average Trading Volume: 1,050,533
Technical Sentiment Signal: Buy
Current Market Cap: $1.9B
Learn more about AUPH stock on TipRanks’ Stock Analysis page.
